C0376322||N-linked glycosylation
C3711414||SV2
C0033618||binding
C0243144||uptake
C0006050||botulinum neurotoxin A
C0006050||Botulinum neurotoxin serotype A1
C0006050||Botulinum neurotoxin serotype A1
C0023636||licensed
C1254351||drug
C0013227||medical
C0026609||motoneurons
C0444626||crystal structure
C0006050||BoNT/A1 receptor
C1514535||binding domain
C1704241||complex
C2325760||neuronal receptor
C0376322||glycosylated
C3711414||human SV2C
C0006050||Botulinum neurotoxin serotype A1
C0030956||peptide moiety
C0032594||N-linked glycan
C3711414||SV2
C0032594||N-glycan
C3711414||SV2
C0597298||isoforms
C0042567||vertebrates
C0006050||Botulinum neurotoxin serotype A1
C0033618||binding
C0027882||neurons
C0235032||neurotoxicity
C0032594||glycan
C0033618||binding
C3711414||SV2
C0086418||human
C0006050||Botulinum neurotoxin serotype A1
C0475463||neutralizing antibody
C0023636||licensed
C1254351||antibotulism drug
C1752856||host-pathogen interactions
C0033666||post-translational modifications
C0597358||receptor binding
C1705285||genetic changes
C0597298||isoforms
C0597357||receptors